Note: This column describes the author’s own experiences with Rituxan (rituximab) and thoughts on other treatments. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Four and a half years ago, I would have taken any route that promised a chance…
Zenas Biopharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its experimental injection therapy, obexelimab, for immunoglobulin G4-related disease (IgG4-RD). “Our obexelimab [biologics license application] submission brings us one step closer to our goal of delivering this…
A new imaging technique shows promise for assessing disease activity and organ involvement in immunoglobulin G4-related disease (IgG4-RD). Compared with biopsy results, the [18F]FAPI PET/CT scan was 100% accurate in detecting lesions in various organs, including the lung, liver, muscles, pancreas, and kidney. The researchers developed a disease activity…
Get regular updates to your inbox.
